Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell with a price target of EUR 100, up from EUR 85, following the company’s “solid” Q4 ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com.
Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their ...
Sanofi SA (SNY) stock saw a decline, ending the day at $52.15 which represents a decrease of $-0.82 or -1.55% from the prior close of $52.97. The stock opened at $52.84 and touched a low of $52.14 ...
Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for ...
The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback